APEIRON Capital Ltd’s BioNTech BNTX Stock Holding History

APEIRON Capital Ltd’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-21,300	Closed	-$2.87M	–	10
2022 Q3	$2.87M	Hold	21,300	–	–	1.91%	10
2022 Q2	$3.18M	Hold	21,300	–	–	1.94%	12
2022 Q1	$3.63M	Hold	21,300	–	–	1.61%	14
2021 Q4	$5.49M	Buy	21,300 +700	+3%	+$192K	1.62%	11
2021 Q3	$5.62M	Buy	+20,600	New	+$6.55M	1.48%	12

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

APEIRON Capital Ltd's BNTX Position: Q4 2022 in Review

APEIRON Capital Ltd sold out of BioNTech (BNTX) in Q4 2022, closing a stake of 21,300 shares — an estimated $2.87M sold.

APEIRON Capital Ltd first reported a position in BNTX in Q3 2021 and held it in 5 quarters. The position peaked at $5.62M in Q3 2021. 320 funds tracked by Wall St. Rank hold BNTX as of Q4 2022.

APEIRON Capital Ltd reported no remaining BioNTech position as of Q4 2022 after selling out during the quarter.
APEIRON Capital Ltd sold 21,300 BioNTech shares in Q4 2022, an estimated $2.87M.
APEIRON Capital Ltd first reported a position in BioNTech in Q3 2021 and held it in 5 quarters.
APEIRON Capital Ltd's BioNTech position peaked at $5.62M in Q3 2021.
320 funds tracked by Wall St. Rank held BioNTech as of Q4 2022.

Based on APEIRON Capital Ltd's 13F filing for Q4 2022, filed 18 Jan 2023.